mezigdomide + carfilzomib + dexamethasone

Mezigdomide + carfilzomib + dexamethasone is an investigational, three-drug combination for the treatment of relapsed or refractory multiple myeloma. **Mezigdomide** is an oral cereblon E3 ligase modulator (CELMoD) that induces maximal degradation of Ikaros and Aiolos transcription factors, leading to increased apoptosis of multiple myeloma cells and immune-stimulatory effects. **Carfilzomib** is a selective proteasome inhibitor that induces apoptosis by blocking protein degradation in cancer cells, and **dexamethasone** is a synthetic glucocorticoid corticosteroid that reduces inflammation and enhances cancer cell death. This combination (referred to as MeziKd) is under investigation in multiple phase 1/2 and phase 3 clinical trials. It is designed for patients with multiple myeloma who are refractory or have relapsed after prior therapies, including lenalidomide and anti-CD38 monoclonal antibodies[1][2][4][5][7].

Brand names

MeziKd

Other names

mezigdomide + carfilzomib + dexamethasoneMeziKD